Prelude Capital Management’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $223K | Buy |
+15,940
| New | +$223K | 0.02% | 750 |
|
|
2024
Q3 | – | Sell |
-10,343
| Closed | -$240K | – | 1239 |
|
|
2024
Q2 | $240K | Sell |
10,343
-26
| -0.3% | -$604 | 0.02% | 819 |
|
|
2024
Q1 | $213K | Buy |
10,369
+25
| +0.2% | +$513 | 0.01% | 966 |
|
|
2023
Q4 | $222K | Buy |
10,344
+40
| +0.4% | +$858 | 0.01% | 776 |
|
|
2023
Q3 | $213K | Sell |
10,304
-335
| -3% | -$6.91K | 0.01% | 732 |
|
|
2023
Q2 | $314K | Sell |
10,639
-700
| -6% | -$20.7K | 0.02% | 532 |
|
|
2023
Q1 | $261K | Buy |
11,339
+3,996
| +54% | +$92.1K | 0.02% | 634 |
|
|
2022
Q4 | $204K | Buy |
+7,343
| New | +$204K | 0.01% | 829 |
|
|
2022
Q1 | – | Sell |
-9,610
| Closed | -$429K | – | 1602 |
|
|
2021
Q4 | $429K | Buy |
9,610
+3,598
| +60% | +$161K | 0.01% | 863 |
|
|
2021
Q3 | $303K | Buy |
6,012
+1,029
| +21% | +$51.9K | 0.01% | 851 |
|
|
2021
Q2 | $391K | Buy |
+4,983
| New | +$391K | 0.01% | 860 |
|
|
2021
Q1 | – | Sell |
-2,950
| Closed | -$247K | – | 1169 |
|
|
2020
Q4 | $247K | Sell |
2,950
-6,150
| -68% | -$515K | 0.01% | 589 |
|
|
2020
Q3 | $326K | Sell |
9,100
-1,809
| -17% | -$64.8K | 0.02% | 368 |
|
|
2020
Q2 | $264K | Buy |
+10,909
| New | +$264K | 0.01% | 430 |
|
|
2019
Q2 | – | Sell |
-4,229
| Closed | -$98K | – | 1349 |
|
|
2019
Q1 | $98K | Buy |
4,229
+2,252
| +114% | +$52.2K | 0.01% | 634 |
|
|
2018
Q4 | $41K | Buy |
+1,977
| New | +$41K | ﹤0.01% | 851 |
|